Orano Med Expands Cancer Research and Radiopharmaceutical Facility in Plano, Texas

Orano Med’s Expansion in Texas

Announcement

Orano Group’s subsidiary, Orano Med, expanded its Research and Development center to Plano, Texas (US) the new center, inaugurated to provide facilities for preclinical research and the development of radiopharmaceuticals. The center will focus on alpha therapies with the help of lead-212 (212Pb), which is a promising and innovative concept against several types of cancer. The site was introduced to the R&D teams of Orano Med, along with its subsidiary manufacturing customized chelating agents, macrocyclics.

R&D Center

Orano Group invested $5 million in its expansion of the R&D center, which is 11,000 ft2. New laboratory space is up to 5,000 ft2, providing double the good manufacturing practice (GMP) production potential for supplying early clinical trials. Further, 5,500 ft2 for new office space has been an addition for the site’s growing team. The team's headcount has increased in the past four years. The center is more spacious, with a 50% increase in space in comparison to the pre-existing facilities.

Orano Med’s R&D Platform

Orano Med’s R&D platform is an integration of smart equipment with an experienced team to advance and enhance the upgradation of next-gen cancer therapies. The company is capable of massive preclinical development studies, including chemistry and in vivo, as well as manufacturing and controls studies, on-site. Orano Med initiates collaborative developments with pharmaceutical and biotech partners and conducts in-house research programs. This integrated concept is transitioning the process from research to the clinical phases. The main mission of the research and development center is to develop therapeutic. The facilities of this center also resemble a production hub for 212 drug candidates to conduct early-stage clinical trials in the US.

The expansion shows Orano Med’s valuable commitment and dedication to expanding innovation in radioligand therapies, promoting the development of alternatives and other treatment options for patients globally.

Views and Statements

Chief Scientific Officer of Orano Med, Julien Torgue, said, “The entry of our R&D center is uplifting our ability to upgrade lead-212-based radioligand therapies by availing required resources to advance the extensive drug candidates through the clinic for our teams. The platform integrates a scientific strategy with the smart equipment. The company is capable of collaboration and internal development.”

President and Chief Executive Officer of Orano Med, Arnaud Lesegretain, said, “The expansion leads Orano Med towards growth in Plano City. This city has been a part of the inception of our company around 15 years ago.”